Skip to main content
SpringerLink
Log in

Immunomodulatory Therapy in Uveitis

  • Chapter
Uveitis and Immunological Disorders

Part of the book series: Essentials in Ophthalmology ((ESSENTIALS))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Akpek EK, Baltatzis S, Yang J, et al. (2001) Long-term immunosuppressive treatment of serpiginous choroiditis. Ocul Immunol Inflamm 9:153–167

    Article  PubMed  Google Scholar 

  2. Akpek EK, Ilhan Sarac O (2003) New treatments for serpiginous choroiditis. Curr Opin Ophthalmol 14:128–131

    Article  PubMed  Google Scholar 

  3. Akpek EK, Jabs DA, Tessler HH, et al. (2002) Successful treatment of serpiginous choroiditis with alkylating agents. Ophthalmology 109:1506–1513

    Article  PubMed  Google Scholar 

  4. Arnett HA, Mason J, Marino M, et al. (2001) TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 4:1116–1122

    Article  PubMed  Google Scholar 

  5. Baltatzis S, Tufail F, Yu EN, et al. (2003) Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 110:1061–1065

    Article  PubMed  Google Scholar 

  6. BenEzra D, Cohen E, Chajek T, et al. (1988) Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. Transplant Proc 20:136–143

    Google Scholar 

  7. Benitez Del Castillo JM, Garcia Sanchez J, Iradier T, et al. (2000) Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye 14:340–343

    PubMed  Google Scholar 

  8. Bom S, Zamiri P, Lightman S (2001) Use of methotrexate in the management of sight-threatening uveitis. Ocul Immunol Inflamm 9:35–40

    Article  PubMed  Google Scholar 

  9. Brock N (1989) Oxazaphosphorine cytostatics: past-present-future. Seventh Cain Memorial Award lecture. Cancer Res 49:1–7

    PubMed  Google Scholar 

  10. Cannon J, Linke CA, Cos LR (1991) Cyclophosphamide-associated carcinoma of urothelium: modalities for prevention. Urology 38:413–416

    PubMed  Google Scholar 

  11. Caspi RR (2002) Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis. Int Rev Immunol 21:197–208

    PubMed  Google Scholar 

  12. Christmas NJ, Oh KT, Oh DM, et al. (2002) Long-term follow-up of patients with serpiginous choroiditis. Retina 22:550–556

    PubMed  Google Scholar 

  13. Clements PJ, Davis J (1986) Cytotoxic drugs: their clinical application to the rheumatic diseases. Semin Arthritis Rheum 15:231–254

    Article  PubMed  Google Scholar 

  14. Deeg CA, Thurau SR, Gerhards H, et al. (2002) Uveitis in horses induced by interphotoreceptor retinoid-binding protein is similar to the spontaneous disease. Eur J Immunol 32:2598–2606

    Article  PubMed  Google Scholar 

  15. Eigler A, Sinha B, Hartmann G, et al. (1997) Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 18:487–492

    Article  PubMed  Google Scholar 

  16. El Shabrawi Y, Hermann J (2002) Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 109:2342–2346

    Article  PubMed  Google Scholar 

  17. Estrach C, Mpofu S, Moots RJ (2002) Behcet's syndrome: response to infliximab after failure of etanercept. Rheumatology (Oxford) 41:1213–1214

    Article  Google Scholar 

  18. Foroozan R, Buono LM, Sergott RC, et al. (2002) Retrobulbar optic neuritis associated with infliximab. Arch Ophthalmol 120:985–987

    PubMed  Google Scholar 

  19. Foster CS, Tufail F, Waheed NK, et al. (2003) Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 121:437–440

    Article  PubMed  Google Scholar 

  20. Frassanito MA, Dammacco R, Fusaro T, et al. (2003) Combined cyclosporin-A/prednisone therapy of patients with active uveitis suppresses IFN-gamma production and the function of dendritic cells. Clin Exp Immunol 133:233–239

    Article  PubMed  Google Scholar 

  21. Fries W, Giofre MR, Catanoso M, et al. (2002) Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab. Am J Gastroenterol 97:499–500

    PubMed  Google Scholar 

  22. Gion N, Stavrou P, Foster CS (2000) Immunomodulatory therapy for chronic tubulointerstitial nephritis-associated uveitis. Am J Ophthalmol 129:764–768

    Article  PubMed  Google Scholar 

  23. Goldstein DA, Fontanilla FA, Kaul S, et al. (2002) Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology 109:370–377

    Article  PubMed  Google Scholar 

  24. Greiner K, Murphy CC, Willermain F, et al. (2004) Anti-TNFalpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci 45:170–176

    Article  PubMed  Google Scholar 

  25. Greiner K, Varikkara M, Santiago C, et al. (2002) Efficiency of mycophenolate mofetil in the treatment of intermediate and posterior uveitis. Ophthalmologe 99:691–694

    Article  PubMed  Google Scholar 

  26. Guex Crosier Y, Raber J, Chan CC, et al. (1997) Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol 158:452–458

    PubMed  Google Scholar 

  27. Hamuryudan V, Mat C, Saip S, et al. (1998) Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128:443–450

    PubMed  Google Scholar 

  28. Hanke JH, Nichols LN, Coon ME (1992) FK506 and rapamycin selectively enhance degradation of IL-2 and GM-CSF mRNA. Lymphokine Cytokine Res 11:221–231

    Google Scholar 

  29. Hudde T, Heinz C, Neudorf U, et al. (2002) Tubulointerstitial nephritis and uveitis (TINU syndrome) — comorbidity and complications in four patients. Klin Monatsbl Augenheilkd 219:528–532

    Article  PubMed  Google Scholar 

  30. Isnard Bagnis C, Tezenas du Montcel S, Beaufils H, et al. (2002) Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J Am Soc Nephrol 13:2962–2968

    PubMed  Google Scholar 

  31. Jordan JF, Walter P, Ayertey HD, et al. (2003) Intermediate uveitis in childhood preceding the diagnosis of multiple sclerosis: a 13-year follow-up. Am J Ophthalmol 135:885–886

    PubMed  Google Scholar 

  32. Joseph A, Raj D, Dua HS, et al. (2003) Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 110:1449–1453

    PubMed  Google Scholar 

  33. Kaklamani VG, Kaklamanis PG (2001) Treatment of Behcet's disease — an update. Semin Arthritis Rheum 30:299–312

    PubMed  Google Scholar 

  34. Kaplan Messas A, Barkana Y, Avni I, et al. (2003) Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm 11:131–139

    PubMed  Google Scholar 

  35. Kari JA, Shah V, Dillon MJ (2001) Behcet's disease in UK children: clinical features and treatment including thalidomide. Rheumatology (Oxford) 40:933–938

    Article  PubMed  Google Scholar 

  36. Kilmartin DJ, Fletcher ZJ, Almeida JA, et al. (2001) CD69 expression on peripheral CD4+ T cells parallels disease activity and is reduced by mycophenolate mofetil therapy in uveitis. Invest Ophthalmol Vis Sci 42:1285–1292

    PubMed  Google Scholar 

  37. Kiss S, Letko E, Qamruddin S, et al. (2003) Long-term progression, prognosis, and treatment of patients with recurrent ocular manifestations of Reiter's syndrome. Ophthalmology 110:1764–1769

    Article  PubMed  Google Scholar 

  38. Klausner JD, Freedman VH, Kaplan G (1996) Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. Clin Immunol Immunopathol 81:219–223

    Article  PubMed  Google Scholar 

  39. Kotter I, Zierhut M, Eckstein AK, et al. (2003) Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87:423–431

    Article  PubMed  Google Scholar 

  40. Kulkarni P (2001) Review: uveitis and immunosuppressive drugs. J Ocul Pharmacol Ther 17:181–187

    Article  PubMed  Google Scholar 

  41. Larkin G, Lightman S (1999) Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology 106:370–374

    PubMed  Google Scholar 

  42. Lim WS, Powell RJ, Johnston ID (2002) Tuberculosis and treatment with infliximab. N Engl J Med 346:623–626

    Article  Google Scholar 

  43. Liu J (1993) FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol Today 14:290–295

    Article  PubMed  Google Scholar 

  44. Masli S, Turpie B, Streilein JW (2003) By altering TNFR2:TNFR1 expression, TGFb prevents ACAID-inducing antigen presenting cells from secreting IL-12. Invest Ophthalmol Vis Sci E-Abstract 44:990

    Google Scholar 

  45. Michel S-S, Ekong A, Baltatzis S, et al. (2002) Multifocal choroiditis and panuveitis: immunomodulatory therapy. Ophthalmology 109:378–383

    Article  PubMed  Google Scholar 

  46. Mikuls TR, Moreland LW (2003) Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis. Drug Saf 26:23–32

    PubMed  Google Scholar 

  47. Miserocchi E, Baltatzis S, Ekong A, et al. (2002) Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience. Ophthalmology 109:137–142

    Article  PubMed  Google Scholar 

  48. Mudun BA, Ergen A, Ipcioglu SU, et al. (2001) Short-term chlorambucil for refractory uveitis in Behcet's disease. Ocul Immunol Inflamm 9:219–229

    Article  PubMed  Google Scholar 

  49. Munoz Fernandez S, Hidalgo V, Fernandez Melon J, et al.(2003) Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol 30:1277–1279

    PubMed  Google Scholar 

  50. Nussenblatt RB, Fortin E, Schiffman R, et al. (1999) Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A 96:7462–7466

    Article  PubMed  Google Scholar 

  51. Nussenblatt RB, Gery I, Weiner HL, et al. (1997) Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am J Ophthalmol 123:583–592

    PubMed  Google Scholar 

  52. Nussenblatt RB, Palestine AG, Rook AH, et al. (1983) Treatment of intraocular inflammatory disease with cyclosporin A. Lancet 2:235–238

    Article  PubMed  Google Scholar 

  53. Nussenblatt RB, Thompson DJ, Li Z, et al. (2003) Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 21:283–293

    Article  PubMed  Google Scholar 

  54. Nussenblatt RB, Whitcup SM, de Smet MD, et al. (1996) Intraocular inflammatory disease (uveitis) and the use of oral tolerance: a status report. Ann N Y Acad Sci 778:325–337

    PubMed  Google Scholar 

  55. Ozdal PC, Ortac S, Taskintuna I, et al. (2002) Long-term therapy with low dose cyclosporin A in ocular Behcet's disease. Doc Ophthalmol 105:301–312

    Article  PubMed  Google Scholar 

  56. Patil CR, Bhise SB (2003) Re-emergence of thalidomide. Ind J Pharmacol 35:204–212

    Google Scholar 

  57. Qi S, Xu D, Peng J, et al. (2000) Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono-and combination therapy in prolongation of renal allograft survival in the monkey. Transplantation 69:1275–1283

    Article  PubMed  Google Scholar 

  58. Reddy AR, Backhouse OC (2003) Does etanercept induce uveitis? Br J Ophthalmol 87:925

    Article  Google Scholar 

  59. Reiff A (2003) Long-term outcome of etanercept therapy in children with treatment-refractory uveitis. Arthritis Rheum 48:2079–2080

    Article  PubMed  Google Scholar 

  60. Saenz A, Ausejo M, Shea B, et al. (2000) Pharmacotherapy for Behcet's syndrome. Cochrane Database Syst Rev 2

    Google Scholar 

  61. Saito H, Ebinuma H, Satoh I, et al. (2000) Immunological and virological predictors of outcome during interferon-alpha therapy of chronic hepatitis C. J Viral Hepat 7:64–74

    Article  PubMed  Google Scholar 

  62. Samson CM, Waheed N, Baltatzis S, et al. (2001) Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 108:1134–1139

    Article  PubMed  Google Scholar 

  63. Saulsbury FT, Mann JA (2003) Treatment with infliximab for a child with Behcet's disease. Arthritis Rheum 49:599–600

    Article  PubMed  Google Scholar 

  64. Sfikakis PP (2002) Behcet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61Suppl 2:ii51–53

    PubMed  Google Scholar 

  65. Shah SS, Lowder CY, Schmitt MA, et al. (1992) Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 99:1419–1423

    PubMed  Google Scholar 

  66. Sicotte NL, Voskuhl RR (2001) Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57:1885–1888

    PubMed  Google Scholar 

  67. Silman AJ, Petrie J, Hazleman B, et al. (1988) Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 47:988–992

    PubMed  Google Scholar 

  68. Sloper CM, Powell RJ, Dua HS (1999) Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 106:723–728

    Article  PubMed  Google Scholar 

  69. Smith J-R (2002) Management of uveitis in pediatric patients: special considerations. Paediatr Drugs 4:183–189

    PubMed  Google Scholar 

  70. Smith JA, Smith S, Whitcup SM, et al. (2002) The treatment of JRA-associated uveitis with etanercept. Arthritis Rheum 46:S482

    Article  Google Scholar 

  71. Stawell R (2003) Methotrexate in inflammatory eye disease. Ocul Immunol Inflamm 11:79–82

    Article  PubMed  Google Scholar 

  72. Stockman GD, Heim LR, South MA, et al. (1973) Differential effects of cyclophosphamide on the B and T cell compartments of adult mice. J Immunol 110:277–282

    PubMed  Google Scholar 

  73. Taniguchi M, Harada M, Kojo S, et al. (2003) The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 21:483–513

    Article  PubMed  Google Scholar 

  74. ten Tusscher MP, Jacobs PJ, Busch MJ, et al. (2003) Bilateral anterior toxic optic neuropathy and the use of infliximab. BMJ 326:579

    Article  PubMed  Google Scholar 

  75. Thurau SR, Diedrichs-Möhring M, Fricke H, et al. (1999) Oral tolerance with an HLA-peptide mimicking retinal autoantigen as a treatment of autoimmune uveitis. Immunol Lett 68:205–212

    Article  PubMed  Google Scholar 

  76. Thurau SR, Wildner G (2003) An HLA-peptide mimics organ-specific antigen in autoimmune uveitis: its role in pathogenesis and therapeutic induction of oral tolerance. Autoimm Rev 2:171–176

    Article  Google Scholar 

  77. Tseng S, Pak G, Washenik K, et al. (1996) Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 35:969–979

    Article  PubMed  Google Scholar 

  78. Uchio E, Matsumoto T, Tanaka SI, et al. (1999) Soluble intercellular adhesion molecule-1 (ICAM-1), CD4, CD8 and interleukin-2 receptor in patients with Behcet's disease and Vogt-Koyanagi-Harada's disease. Clin Exp Rheumatol 17:179–184

    PubMed  Google Scholar 

  79. Weiner HL (2001) Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. Microbes Infect 3:947–954

    Article  PubMed  Google Scholar 

  80. Wildner G, Thurau SR (1994) Cross-reactivity between an HLA-B27-derived peptide and a retinal autoantigen peptide: a clue to major histocompatibility complex association with autoimmune disease. Eur J Immunol 24:2579–2585

    PubMed  Google Scholar 

  81. Wilson SB, Kent SC, Patton KT, et al. (1998) Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature 391:177–181

    Article  PubMed  Google Scholar 

  82. Zierhut M, Stubiger N, Aboalchamat W, et al. (2001) Immunosuppressive therapy with mycophenolate mofetil (CellCept) in treatment of uveitis. Ophthalmologe 98:647–651

    Article  PubMed  Google Scholar 

Download references

Authors
  1. Stephan R. Thurau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerhild Wildner
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Ophthalmology, Augenklinik Charité, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany

    Günther K. Krieglstein MD (Professor) (Professor)

  2. Ophthalmology, Jules Stein Eye Institute, 100 Stein Plaza #2-142, Los Angeles, CA, 90095-7000, USA

    Robert N. Weinreb MD (Professor) (Professor)

  3. Department of Ophthalmology, University of Cologne, Joseph-Stelzmann-Straße 9, 50931, Cologne, Germany

    Uwe Pleyer MD (Professor) (Professor)

  4. Hamilton Glaucoma Center Department of Ophthalmology - 0946, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA, 92093-0946, USA

    Bartly Mondino MD (Professor) (Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Thurau, S.R., Wildner, G. (2005). Immunomodulatory Therapy in Uveitis. In: Krieglstein, G.K., Weinreb, R.N., Pleyer, U., Mondino, B. (eds) Uveitis and Immunological Disorders. Essentials in Ophthalmology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26752-2_16

Download citation

  • DOI: https://doi.org/10.1007/3-540-26752-2_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-20045-1

  • Online ISBN: 978-3-540-26752-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation